Enclomiphene Citrate Cost in Georgia 2026

What Is Enclomiphene Citrate and Why Does It Cost What It Does in Georgia?

Enclomiphene citrate is the trans-stereoisomer of clomiphene, and it works by blocking estrogen receptors at the hypothalamus, which raises gonadotropin-releasing hormone pulse frequency, lifts LH and FSH, and drives endogenous testosterone production without suppressing sperm output the way exogenous testosterone does. Androxal (enclomiphene citrate) received FDA approval for secondary hypogonadism in adult men with overweight or obesity. Off-label prescribing for other forms of male hypogonadism is common and clinically supported by published data.

Pricing in Georgia reflects two distinct supply chains. Brand-name Androxal carries a manufacturer list price that few patients pay directly. Compounded enclomiphene citrate, prepared by state-licensed 503A pharmacies, costs roughly $90 per month for a 12.5 to 25 mg daily dose. That gap exists because 503A compounding pharmacies dispense on a per-prescription basis and do not carry commercial distribution overhead. The FDA's framework for 503A compounding pharmacies defines the legal boundaries these pharmacies operate within.

Kim et al. published a key randomized trial in BJU International (2016, N=124) showing that enclomiphene citrate 12.5 mg and 25 mg daily restored serum testosterone to normal range in men with secondary hypogonadism more effectively than topical testosterone gel, while preserving sperm concentration. That trial is the most-cited efficacy reference clinicians in Georgia use to justify prescribing. The effect on sperm preservation matters clinically because testosterone replacement therapy suppresses spermatogenesis in roughly 90% of men within six months, per data published in Fertility and Sterility.

Cost is also shaped by pharmacy type. Independent compounding pharmacies in Atlanta, Savannah, and Augusta price slightly differently. Telehealth platforms that include dispensing partnerships may bundle the physician visit and the compound, dropping the effective per-month outlay below $90 in some cases.

Exact Georgia Prices for Enclomiphene Citrate in 2026

Georgia patients have three realistic supply options in 2026, each at a different price point.

Compounded 503A pharmacies (most common route): approximately $90/month. A licensed Georgia 503A pharmacy compounds enclomiphene citrate as an oral capsule or tablet, typically in 12.5 mg or 25 mg strengths. Ninety capsules at 12.5 mg runs near $90; 25 mg capsules land in the same range at most pharmacies because the active ingredient cost is modest and labor drives pricing. USP compounding standards that these pharmacies follow add overhead versus a simple tablet press, but not dramatically so.

Brand-name Androxal at retail: variable, typically $300, $600+ per month without coverage. Few Georgia patients pay this out of pocket. Androxal is prescribed when a patient's insurer specifically covers it or when a clinician believes compounded product is contraindicated.

Telehealth-bundled plans: $99, $180/month all-in. Several telehealth platforms serving Georgia residents bundle the prescriber consultation, ongoing monitoring labs, and a 503A compounded supply into a monthly subscription. The American Urological Association's 2018 testosterone deficiency guideline acknowledges that convenience and access to specialist-level prescribing are legitimate patient-centered considerations, particularly for men in rural Georgia counties with limited endocrinology access.

A 2023 analysis in the Journal of Urology found that men treated with selective estrogen receptor modulators (SERMs) for hypogonadism had a mean treatment duration of 14 months, meaning annual costs matter as much as monthly sticker prices. At $90/month, a 14-month course totals $1,260 before any discount programs.

The HealthRX clinical team evaluates Georgia patients on a three-tier access framework: (1) does the patient qualify for a compounded 503A prescription based on clinical need documented in the chart; (2) does the patient's commercial insurer have a prior-authorization pathway worth pursuing; (3) is a telehealth-bundled plan more cost-effective given the patient's lab-monitoring frequency. Most patients land in tier 1 or tier 3.

Does Georgia Medicaid Cover Enclomiphene Citrate?

Georgia Medicaid does not cover enclomiphene citrate for secondary hypogonadism. The Georgia Department of Community Health Preferred Drug List classifies enclomiphene as off-label for hypogonadism and excludes it from the covered formulary. Georgia DCH's pharmacy program restricts SERM coverage to oncology indications (specifically breast cancer adjuvant therapy with tamoxifen or toremifene) and type 2 diabetes-related fertility contexts, not male hypogonadism.

This creates a hard barrier for roughly 1.6 million Georgia Medicaid enrollees who are adult men. CDC prevalence data estimates that 5 to 10% of men in the reproductive age range have clinically low testosterone, meaning tens of thousands of Georgia Medicaid enrollees could theoretically benefit but cannot access coverage.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends SERMs as an alternative to exogenous testosterone in men who wish to preserve fertility, citing evidence grade 2|QQQO. Medicaid's formulary decisions have not caught up with that recommendation in Georgia. Advocates at RESOLVE: The National Infertility Association have lobbied for state Medicaid programs to expand SERM coverage, but Georgia has not acted on this as of the 2026 plan year.

No Georgia Medicaid waiver program currently covers enclomiphene citrate for hypogonadism. Patients on Medicaid should ask their prescriber about cost-assistance programs through the manufacturer (Repros Therapeutics) or through 503A pharmacy sliding-scale pricing.

Is Compounded Enclomiphene Citrate Legal in Georgia?

Compounded enclomiphene citrate is legal in Georgia when dispensed by a state-licensed 503A pharmacy with a valid patient-specific prescription from a licensed Georgia prescriber. Three conditions must be met simultaneously: the pharmacy holds an active Georgia Board of Pharmacy license; a valid prescriber-patient relationship exists (in-person exam or a compliant telehealth encounter); and the compound is prepared according to USP <795> non-sterile compounding standards.

The FDA's guidance on compounding of drug products states that 503A pharmacies may compound copies of commercially available drugs when the prescriber documents a specific clinical rationale for the patient. Because Androxal's brand-name availability is limited and access is inconsistent across Georgia counties, that rationale is typically straightforward to document.

Georgia does not independently prohibit enclomiphene compounding beyond federal 503A requirements. The Georgia Drugs and Narcotics Agency enforces state pharmacy law, which defers to federal compounding frameworks for Schedule-unscheduled compounds. Enclomiphene is not a scheduled substance under the DEA Controlled Substances Act schedules, so no DEA registration is required by the dispensing pharmacy beyond standard pharmacy licensure.

503B outsourcing facilities (large-scale compounders registered with the FDA) may also supply enclomiphene citrate to Georgia medical practices under the Drug Quality and Security Act, but most patients receive 503A patient-specific compounds.

A 2022 review in Translational Andrology and Urology noted that SERM-based treatment of male hypogonadism has grown substantially since 2018, partly because compounding access reduced cost barriers to non-suppressive testosterone therapy.

Telehealth Access to Enclomiphene Citrate in Georgia

Telehealth prescribing of enclomiphene citrate is legal in Georgia. A Georgia-licensed prescriber may evaluate a patient via synchronous audio-video telehealth, review lab work, and write a valid prescription for enclomiphene citrate under Georgia's telehealth statute (O.C.G.A. § 33-24-56.4) and the Georgia Composite Medical Board's telemedicine policy.

Federal rules expanded telehealth prescribing during the COVID-19 public health emergency, and many of those expansions have been extended. The DEA's telemedicine prescribing rules apply to controlled substances; enclomiphene is not controlled, so the baseline telehealth prescribing standard (valid prescriber-patient relationship, licensure in the patient's state) applies without the added DEA layers.

In practice, a Georgia patient can complete a HealthRX intake visit, submit serum testosterone, LH, FSH, and estradiol labs at a local LabCorp or Quest Diagnostics draw site, and receive an enclomiphene citrate prescription within 48 to 72 hours of the prescriber reviewing results. The American Association of Clinical Endocrinology's 2022 guidelines recommend baseline testosterone (early morning, two separate draws), LH, FSH, prolactin, and complete metabolic panel before initiating SERM therapy.

Rural Georgia residents benefit most from this model. Georgia has 18 counties classified as primary care Health Professional Shortage Areas by HRSA, and endocrinology specialists are concentrated in Atlanta, Macon, and Savannah metro areas. Telehealth closes that gap without requiring a four-hour round trip.

Commercial Insurance Coverage for Enclomiphene Citrate in Georgia

Most commercial insurance plans sold in Georgia exclude enclomiphene citrate or require prior authorization that is rarely approved for male hypogonadism. The off-label status for most presentations is the primary obstacle. Androxal's FDA label covers secondary hypogonadism in men with overweight or obesity, which does allow for on-label prescribing in eligible patients, but formulary placement is still inconsistent.

Georgia's largest commercial payers (BlueCross BlueShield of Georgia, Anthem, Aetna, Cigna, UnitedHealthcare) each maintain their own drug formularies. None, as of the 2026 plan year, lists enclomiphene citrate on a standard Tier 1 or Tier 2 formulary. Tier 3 or specialty placement, where it exists, typically requires prior authorization with documented serum testosterone below 300 ng/dL on two early-morning draws, confirmed secondary etiology (elevated or normal LH/FSH rather than low), and failure of lifestyle intervention.

The American Urological Association defines hypogonadism treatment criteria that can support a prior-authorization letter. A well-constructed PA letter citing the AUA guideline, the Kim et al. 2016 BJU Int trial data, Endocrine Society 2018 guidelines, and the patient's two qualifying testosterone values has the best chance of approval.

Employer self-funded plans (common among Georgia's large employers such as Georgia-Pacific, Delta Air Lines, and Home Depot) may have more flexibility because they are not subject to Georgia state insurance mandates under ERISA. A benefits coordinator can sometimes add enclomiphene to a self-funded plan's formulary if the employer's pharmacy benefit manager approves it.

Discount Programs and Savings Cards for Georgia Patients

Several cost-reduction options exist for Georgia residents who cannot get insurance coverage.

GoodRx and similar discount platforms apply at independent pharmacies that compound or carry enclomiphene. Savings vary; GoodRx coupons at major chain pharmacies in Atlanta range from 15% to 40% off retail pricing. GoodRx's published price data should be checked at the specific pharmacy, as rates shift monthly.

Manufacturer patient-assistance programs exist for Androxal through Repros Therapeutics. Patients with income at or below 400% of the federal poverty level ($58,320 for a single adult in 2025, per HHS poverty guidelines) may qualify for free or reduced-cost branded product. Applications require prescriber participation.

503A pharmacy sliding-scale pricing is available at a minority of Georgia compounding pharmacies that serve underinsured populations. Patients should ask directly; this is not advertised.

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) cover enclomiphene citrate when prescribed for a qualifying medical condition. IRS Publication 502 lists prescription medications as qualified medical expenses. A patient paying $90/month from an HSA saves the equivalent of their marginal tax rate, typically 22 to 24% for a median Georgia household.

Telehealth subscription bundling is the most consistent cost-reduction strategy. Paying $130/month all-in for visit plus compound versus $90/month compound plus a separate $150, $250 specialist visit every three months makes the bundled model cheaper for most patients over a 12-month horizon.

How to Get the Lowest Possible Price on Enclomiphene Citrate in Georgia

The lowest realistic monthly cost for most Georgia patients is $80, $90 through a 503A compounding pharmacy with a telehealth prescription, paid via HSA or FSA to capture the tax offset. Below is the specific sequence:

1. Obtain a serum testosterone panel (two early-morning draws, minimum 48 hours apart), LH, FSH, and estradiol from a local LabCorp or Quest location. Self-pay lab costs run $40, $80 total through LabCorp's patient pay portal or similar.

2. Complete a telehealth intake with a Georgia-licensed prescriber. HealthRX visits start at $0 for new patients under promotional pricing; standard follow-up visits are $49.

3. Receive the enclomiphene citrate prescription sent directly to a partnered 503A pharmacy. The pharmacy ships directly to your Georgia address, typically within 3, 5 business days.

4. Pay with your HSA or FSA debit card to immediately capture the 22 to 32% tax savings on the $90 monthly cost.

5. Request a follow-up testosterone and LH panel at 6 to 8 weeks. Endocrine Society guidelines specify that treatment response should be confirmed with morning serum testosterone at 3 months.

The American Society for Reproductive Medicine's guidance on male infertility notes that empiric SERM therapy for idiopathic male factor infertility or hypogonadism should be monitored with semen analysis at 3 months and serum testosterone at 6 to 8 weeks, so those lab visits are not optional cost-cutters.

Clinical Monitoring Costs Georgia Patients Should Budget For

Enclomiphene citrate is not a set-and-forget prescription. Georgia patients should budget for ongoing monitoring labs alongside the medication cost itself.

A reasonable annual monitoring budget at standard telehealth self-pay rates:

• Baseline testosterone panel (2 draws): $80 total
• Week 6, 8 testosterone + LH recheck: $40
• Month 3 comprehensive panel (testosterone, LH, FSH, estradiol, CBC, CMP): $90, $120
• Month 6 and month 12 panels: same as month 3

Total first-year lab spend: approximately $290, $350 at self-pay rates.

AACE's 2022 hypogonadism guideline specifically recommends monitoring hematocrit because SERMs, like exogenous testosterone, can raise red blood cell mass in some patients, though the effect is smaller with enclomiphene than with testosterone injections. A 2020 study in the Journal of Sexual Medicine confirmed that enclomiphene's hematocrit effect is clinically modest compared to injectable testosterone, with mean hematocrit increases of less than 2% in treated men over 6 months.

Cochrane's 2021 systematic review on testosterone therapy in men found that hematocrit monitoring and cardiovascular risk assessment are standard-of-care across all testosterone-raising therapies, supporting the monitoring schedule above.

Total first-year cost for a Georgia patient on the compounded enclomiphene route (medication plus monitoring, no insurance): approximately $1,370, $1,430. That compares favorably to testosterone cypionate injection therapy, which at $60, $80/month for medication plus $300, $500/year in clinic injection visits and labs totals $1,020, $1,460 annually, per pharmacy benefit data published in JAMA Network Open (2022).

Enclomiphene Citrate Efficacy Data Georgia Prescribers Cite

Prescribers in Georgia justify enclomiphene citrate by pointing to a consistent clinical trial record.

Kim et al. (BJU Int, 2016, N=124) showed enclomiphene 12.5 mg daily raised mean serum testosterone from 230 ng/dL to 418 ng/dL at 3 months, a statistically significant increase (P<0.001) compared to topical testosterone 1.62% gel, which raised testosterone similarly but reduced sperm concentration by 42% [1]. That sperm-preservation finding is the primary clinical differentiator.

A phase III trial by Wiehle et al. published in Fertility and Sterility (2013, N=163) confirmed that enclomiphene 12.5 mg and 25 mg daily normalized testosterone in 71% and 79% of men respectively at 3 months while maintaining sperm output. The FDA review documents for Androxal cite these trials as the primary basis for approval.

Ramasamy et al. in Fertility and Sterility (2014) reported that clomiphene citrate (the racemic mixture that includes enclomiphene) normalized testosterone in 86% of hypogonadal men at 12 months, supporting longer-term use. The trans-isomer (enclomiphene) shows fewer estrogenic side effects than the cis-isomer (zuclomiphene), making the isolated compound preferable per this 2020 pharmacokinetic analysis in Andrology.

The American Urological Association's male infertility guideline grades SERM therapy for hypogonadotropic hypogonadism as a reasonable first-line option in men desiring fertility preservation, and that language directly supports GA prescriber prior-authorization letters to commercial insurers.